WebTo derive new uricosuric agents, novel phenol derivatives were synthesized to overcome the disadvantages of benzbromarone (BBR), attributed by its structural features. Herein, we … WebDotinurad is a novel uric acid-lowering drug classified as a selective urate reabsorption inhibitor. A pooled analysis was performed on the uric acid-lowering effect of dotinurad in 222 hypertensive patients with gout or asymptomatic hyperuricemia in four clinical trials (NCT02344862, NCT02416167, NCT03100318, NCT03372200).

Dotinurad: a novel selective urate reabsorption inhibitor for the ...

WebThe urate-lowering effect of dotinurad is retained after its long-term administration, and most patients receiving a maintenance dose of 2 or 4 mg once daily achieved target … Web1 ott 2024 · Dotinurad, at doses of 1–30 mg/kg, concomitantly decreased plasma urate levels and increased fractional excretion of urate (FE UA) in a dose-dependent manner. On the contrary, benzbromarone, at a dose of 30 mg/kg, showed a modest effect on … dymchurch road hythe postcode

Dotinurad: a novel selective urate reabsorption inhibitor as a …

WebBackground: Dotinurad is a novel selective urate reabsorption inhibitor that reduces serum urate levels in hyperuricemic patients with or without gout by selectively inhibiting urate … WebObjective: We aimed to assess the relative efficacy and safety of dotinurad (2 mg), benzbromarone (50 mg), and febuxostat (40 mg) in hyperuricemic patients with or without gout. Materials and methods: A Bayesian network meta-analysis was performed to combine direct and indirect evidence from randomized controlled trials (RCTs) to evaluate the … WebDotinurad (Urece) is a drug for the treatment of gout and hyperuricemia. [1] [2] It was developed by Fuji Yakuhin and approved for use in Japan in 2024. [2] [3] The drug is … dymchurch redoubt united kingdom